Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis A Randomized Clinical Trial

Autor: M.E. Otero, M.D. Njoo, J.M. Mommers, Elke M G J de Jong, P.M. Ossenkoppele, Maartje A Berends, Lieke J. van Vugt, Hans Groenewoud, Alfons A den Broeder, Juul M. P. A. van den Reek, M.I.A. Koetsier, Selma Atalay, Peter C.M. van de Kerkhof, Wietske Kievit

Publikováno v: JAMA Dermatol
Jama Dermatology, 156, 4, pp. 393-400
Jama Dermatology, 156, 393-400

Importance Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible. Objective To investigate whether dose reduction (DR) of biologics in patients with stable psoriasis is noninferior

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a6cfb2b8be0d89ef4f9c35ddfa301d6
https://doi.org/10.1001/jamadermatol.2019.4897

Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

Autor: J.M.P.A. van den Reek, P.M. Ossenkoppele, J.M.M. Groenewoud, M.D. Njoo, M.P.M. Andriessen, P.C.M. van de Kerkhof, P.P.M. van Lümig, R.J.B. Driessen, W.P. Arnold, J.M. Mommers, Jeffrey Zweegers, M.A.M. Berends, M.I.A. Koetsier, M.E. Otero, Wietske Kievit, E.M.G.J. de Jong, A.L.A. Kuijpers

Publikováno v: British Journal of Dermatology, 176, 4, pp. 1001-1009
British Journal of Dermatology, 176, 1001-1009

Contains fulltext : 174191.pdf (Publisher’s version ) (Closed access) BACKGROUND: The efficacy of etanercept and ustekinumab in psoriasis has been compared in one randomized controlled trial. Comparison of the long-term effectiveness of biologics i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4ae5d0bd115d5b814fe1ad0ad9b305
https://doi.org/10.1111/bjd.15023

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Autor: Marjolein S. de Bruin-Weller, Marjan de Groot, P.M. Ossenkoppele, Juul M. P. A. van den Reek, G.P.H. Lucker, Phyllis I. Spuls, Peter C.M. van de Kerkhof, H Jorn Bovenschen, Gayle E. van der Kraaij, Wietske Kievit, Ruud L. M. A. Prevoo, Roland J M Mommers, Barbara Horváth, M. David Njoo, Wim J. A. de Kort, Martijn B. A. van Doorn, Elke M G J de Jong, Lieke J. van Vugt

Publikováno v: Acta Dermato-Venereologica, 98(7), 648-654. Medical Journals/Acta D-V
Acta dermato-venereologica, 98(7-8), 648-654. Society for the Publication of Acta Dermato-Venereologica
Acta Dermato-Venereologica, 98, 7, pp. 648-654
Acta Dermato-Venereologica, Vol 98, Iss 7, Pp 648-654 (2018)
Acta Dermato-Venereologica, 98, 648-654
Acta dermato-venereologica, 98(7), 648-654. ACTA DERMATO-VENEREOLOGICA

Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectivenes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46338124ad76cda5a77509fc2a081751
https://pure.eur.nl/en/publications/f57939c0-8ca9-4c64-bca1-4f36e2a8374a

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry

Autor: P.M. Ossenkoppele, P.C.M. van de Kerkhof, P.P.M. van Lümig, Jeffrey Zweegers, Wietske Kievit, M.E. Otero, M.A.M. Berends, E.M.G.J. de Jong, R.J.B. Driessen, M.I.A. Koetsier, J.M.P.A. van den Reek, W.P. Arnold, A.L.A. Kuijpers, M.D. Njoo, L. Weppner-Parren, J.M. Mommers

Publikováno v: British Journal of Dermatology, 175, 340-7
British Journal of Dermatology, 175, 2, pp. 340-7

Contains fulltext : 172038.pdf (Publisher’s version ) (Closed access) BACKGROUND: Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c04ebc7027ca3dc9c144ad0af02f6b6
https://pubmed.ncbi.nlm.nih.gov/27535601

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.